For more information on this story and others, visit www.newsinfusion.com October 22, 2008 - Preliminary results from a large safety study, called the Vaccine Safety Datalink (VSD) project, presented for the first time today by the Centers for Disease Control and Prevention (CDC) at the Advisory Committee on Immunization Practices (ACIP) meeting did not find statistically significant risk for any of the pre-specified adverse events following vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] compared to those who were not vaccinated. This finding was based on more than 375,000 doses of GARDASIL administered.